Comparing a new drug to Padcev for advanced bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug called SYS6002 against the standard treatment Padcev for people with advanced bladder cancer that has already been treated with chemotherapy and immunotherapy. It aims to see if the new drug works better or has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have advanced bladder cancer that has spread and you have already received chemotherapy and an immunotherapy drug.
- You can provide a tissue sample from a previous biopsy or a new one.
- You have at least one tumor that can be measured on scans.
- You are in good enough health to be up and about (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, 9MW2821, against standard chemotherapy for people with advanced bladder cancer that has gotten worse after previous treatments. It aims to see if the new drug works better.
This trial tests a new combination of drugs for bladder cancer. It adds capivasertib, a targeted therapy, to immunotherapy for people whose cancer has not responded to previous treatments.
This trial is testing a new combination of two drugs—9MW2821 (a targeted therapy) and toripalimab (an immunotherapy)—for people with advanced bladder cancer. It aims to see if using them together can help shrink tumors or slow the cancer's growth.
This trial tests a new drug called SYS6002 against standard chemotherapy for patients with advanced bladder cancer (urothelial carcinoma) that has already progressed despite previous treatments. The goal is to see if SYS6002 works better and is safer than chemotherapy.
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced bladder cancer that has stopped responding to platinum chemo and immunotherapy. The goal is to see if the new drug works better.
This trial is for people with advanced bladder cancer (urothelial cancer) that has spread or can't be removed. It tests a new drug called sacituzumab tirumotecan against standard chemotherapy options to see if it works better.
Hear when a new Advanced Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.